Key Strategies for Managing Breast Cancer Brain Metastases
Medscape,
Brain metastases remain a frequent and often fatal consequence of metastatic breast cancer (MBC).
Brain metastases remain a frequent and often fatal consequence of metastatic breast cancer (MBC).
Brain metastases remain a frequent and often fatal consequence of metastatic breast cancer (MBC).
Advertisement Karen Lisa Smith, MD, MPH Vered Stearns, MD The fact that a new guideline for the management of advanced HER2-posit…
Updated Data from Phase 1b Triplet Combination Trial at SABCS; Increased Median PFS to 7.8 Months and ORR to 61 Percent; Median…
Updated Data from Phase 1b Triplet Combination Trial at SABCS; Increased Median PFS to 7.8 Months and ORR to 61 Percent; Median…
GlobeNewswire 2016-12-07 HER2CLIMB is an ongoing randomized, controlled pivotal trial evaluating tucatinib in combination with…
Updated Data from Phase 1b Triplet Combination Trial at SABCS; Increased Median PFS to 7.8 Months and ORR to 61 Percent; Median…
] Updated Data from Phase 1b Triplet Combination Trial at SABCS; Increased Median PFS to 7.8 Months and ORR to 61 Percent…
Updated Data from Phase 1b Triplet Combination Trial at SABCS; Increased Median PFS to 7.8 Months and ORR to 61 Percent; Median…
Updated Data from Phase 1b Triplet Combination Trial at SABCS; Increased Median PFS to 7.8 Months and ORR to 61 Percent; Median…
Updated Data from Phase 1b Triplet Combination Trial at SABCS; Increased Median PFS to 7.8 Months and ORR to 61 Percent; Median…
Updated Data from Phase 1b Triplet Combination Trial at SABCS; Increased Median PFS to 7.8 Months and ORR to 61 Percent; Median…
Updated Data from Phase 1b Triplet Combination Trial at SABCS; Increased Median PFS to 7.8 Months and ORR to 61 Percent; Median…
Updated Data from Phase 1b Triplet Combination Trial at SABCS; Increased Median PFS to 7.8 Months and ORR to 61 Percent; Median…
Updated Data from Phase 1b Triplet Combination Trial at SABCS; Increased Median PFS to 7.8 Months and ORR to 61 Percent; Median…
Updated Data from Phase 1b Triplet Combination Trial at SABCS; Increased Median PFS to 7.8 Months and ORR to 61 Percent; Median…
Cascadian Therapeutics Amends HER2CLIMB Phase 2 Trial of Tucatinib in Metastatic HER2-Positive Breast Cancer to Support…
Approximately 15% of patients with breast cancer have tumors that overexpress the HER2 protein and these patients can benefit…
Approximately 20% of all breast cancers are human epidermal growth factor receptor 2 (HER2)-positive. Prior to the era of HER2-ta…
Across doses n107 48 and 41 of this heavily pretreated patient population that received nivolumab as a single agent was alive…
(MedPage Today) -- The American Society of Clinical Oncology has released two new sets of clinical practice guidelines for the…
Title: Experts Issue Treatment Guidelines for Aggressive Form of Breast Cancer Category: Health News Created: 5/5/2014 4:36:00…
New guidelines have been released to treat HER2-positive breast cancers, which carry a protein that causes them to grow more…
(HealthDay)—Two sets of guidelines for treating patients with an aggressive form of breast cancer have been released by the…
MONDAY, May 5, 2014 -- Two sets of guidelines for treating patients with an aggressive form of breast cancer have been released…
The American Society of Clinical Oncology (ASCO) has issued two clinical practice guidelines on treating women with advanced…
Up to one-fifth of patients will have these 'HER2-positive' tumors, oncologists' group says Source: HealthDay Related…
Up to one-fifth of patients will have these 'HER2-positive' tumors, oncologists' group says